Tumor cell-intrinsic RIG-I signaling governs synergistic effects of immunogenic cancer therapies and checkpoint inhibitors in mice.

Titel:: Tumor cell-intrinsic RIG-I signaling governs synergistic effects of immunogenic cancer therapies and checkpoint inhibitors in mice.
Dokumenttyp:: Letter; Letter; Research Support, Non-U.S. Gov't
Autor(en):: Poeck, Hendrik; Wintges, Alexander; Dahl, Sarah; Bassermann, Florian; Haas, Tobias; Heidegger, Simon
Abstract:: Immunogenic cancer therapies, including radiation and hypomethylating agents, such as 5-azacytidine, rely on tumor cell-intrinsic activation of the RNA receptor RIG-I for their synergism with immune checkpoint inhibitors. Possible RIG-I ligands are small nuclear RNA (snRNA) and endogenous retroviral elements (ERV) leaking from the nucleus during programmed cell death.
Zeitschriftentitel:: Eur J Immunol
Jahr:: 2021
Band / Volume:: 51
Heft / Issue:: 6
Seitenangaben Beitrag:: 1531-1534
Volltext / DOI:: doi:10.1002/eji.202049158
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/33733474
Print-ISSN:: 0014-2980
TUM Einrichtung:: III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
BibTeX

Vorkommen: